Cytodyn Inc (CYDY)

[Bored Lawyer]

I can't join but will listen to the archived recording on CYDY's website.

The primary question I want answered is why the change from 30 to 50 patients on combo and from 100 patients to 300 patients for safety data.

The answer I want to hear is that the FDA required more patients for combo and safety because the company ASKED the FDA for something more with respect to Pro 140 (broader labeling, BTD, something).

The answer I don't want to hear is that the FDA required more patients because the company screwed up the trial (I think this is extremely unlikely), that 50/300 patients was always the plan (which would be troublesome because it was never clearly communicated by the company to investors), or that the increases were just a result of the FDA being the FDA.